The targeted protein degradation enabling technologies market is anticipated to be worth over USD 3.

Roots Analysis has announced the addition of “Targeted Protein Degradation Market, 2021-2030” report to its list of offerings.

Small-molecule-induced protein degradation has been demonstrated to possess the potential to drug a broader range of proteinaceous biological targets. It involves the selective recruitment of the body’s inherent protein degradation pathways, to eliminate disease causing / associated proteins, using bifunctional small molecule drugs. Presently, the most popular and promising class of interventions in this field of research, is proteolysis targeting chimeras (PROTACs); these can simultaneously bind a target protein and an E3-ubiquitin ligase, and thereby, facilitate the selective ubiquitination and eventual proteasome-mediated degradation of the target protein. The most interesting feature of this mechanism of drug action is the fact that PROTACs and other targeted protein degraders can eliminate protein targets regardless of their function.

To order this 330+ page report, which features 115+ figures and 180+ tables, please visit –

Key Market Insights

Presently, more than 150 targeted protein degradation-based therapeutics are currently under development
Around 75% of the aforementioned candidates are in the preclinical and discovery stages, followed by those that are being evaluated in clinical trials (25%). The these degrader molecules are PROTAC (26), followed by DUB inhibitors (15%), protein homeostatic modulators (14%) and SERDs/SARDs (13%).

Over 40 targeted protein degradation enabling technologies are presently available / under development
Of these, the PROTAC® platform is presently considered the most popular, with 15 product candidates, developed using the same technology, under investigation. On the other hand, there are presently 10 technologies that are designed to design / develop DUB inhibitors.

Leave a Reply

Your email address will not be published. Required fields are marked *